Xalkori (Crizotinib) 20mg – Treatment for ALK+/ROS1+ Lung Cancer and ALK+ Lymphoma

XALKORI (crizotinib) is indicated for the treatment of specific types of cancer that involve genetic alterations in the ALK or ROS1 genes.
It is used in:

• Adults with metastatic non-small cell lung cancer (NSCLC) that is ALK-positive or ROS1-positive.

• Pediatric patients (aged 1 year and older) and young adults with systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive, relapsed or refractory.

• Adults and pediatric patients (aged 1 year and older) with ALK-positive inflammatory myofibroblastic tumors (IMT) that are unresectable, recurrent, or refractory.

Xalkori is a targeted therapy that inhibits the activity of the ALK and ROS1 proteins, which are responsible for the uncontrolled growth of cancer cells in these conditions.